Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04184622 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,539
- Enrollment target
NCT04184622 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 2,539 participants.
The verdict
NCT04184622, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,539 participants
- Enrollment target
Study Summary
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,539 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2024-07-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04184622
The ClinicalTrials.gov registry entry for NCT04184622 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,539 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04184622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04184622 about?
NCT04184622 is a clinical study titled "A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight". This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will c...
What is the current status of trial NCT04184622?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,539 participants. The study started on 2019-12-04. Estimated completion is 2024-07-06.
What interventions are being tested in trial NCT04184622?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT04184622?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.